Thromboprophylaxis in multiple myeloma

References

• Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111(6):2962–2972.
   PubMed Web of Science ®Google Scholar
• Cesarman-Maus G, Braggio E, Fonseca R. Thrombosis in multiple myeloma (MM). Hematology. 2012;17(sup1):S177–S80.
   PubMed Web of Science ®Google Scholar
• De Stefano V, Za T, Rossi E. Venous thromboembolism in multiple myeloma. Semin Thromb Hemost. 2014;40(3):338–347.
   PubMed Web of Science ®Google Scholar
• Li W, Cornell RF, Lenihan D, et al. Cardiovascular complications of novel multiple myeloma treatments. Circulation. 2016;133(9):908–912.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Jacobus S, Callander NS, Eastern Cooperative Oncology Group, et al. Eastern cooperative oncology group. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11(1):29–37.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357(21):2123–2132.
   PubMed Web of Science ®Google Scholar
• Kristinsson SY. Thrombosis in multiple myeloma. Hematology Am Soc Hematol Educ Program. 2010;2010(1):437–444.
   PubMedGoogle Scholar
• Kristinsson SY, Pfeiffer RM, Björkholm M, et al. Thrombosis is associated with inferior survival in multiple myeloma. Haematologica. 2012;97(10):1603–1607.
   PubMed Web of Science ®Google Scholar
• Schoen MW, Carson KR, Luo S, et al. Venous thromboembolism in multiple myeloma is associated with increased mortality. Res Pract Thromb Haemost. 2020;4(7):1203–1210.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Rajkumar SV, San Miguel JF, et al. International myeloma working group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014;32(6):587–600.
   PubMed Web of Science ®Google Scholar
• Terpos E, Kleber M, Engelhardt M, on behalf of the European Myeloma Network, et al. European myeloma network guidelines for the management of multiple myeloma-related complications. Haematologica. 2015;100(10):1254–1266.
   PubMed Web of Science ®Google Scholar
• Bradbury CA, Craig Z, Cook G, et al. Thrombosis in patients with myeloma treated in the myeloma IX and myeloma XI phase 3 randomized controlled trials. Blood. 2020;136(9):1091–1104.
   PubMed Web of Science ®Google Scholar
• Fotiou D, Gavriatopoulou M, Terpos E. Multiple myeloma and thrombosis: prophylaxis and risk prediction tools. Cancers. 2020;12(1):191.
   PubMed Web of Science ®Google Scholar
• Anaissie EJ, Coleman EA, Goodwin JA, et al. Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis. Cancer. 2012;118(2):549–557.
   PubMed Web of Science ®Google Scholar
• Cortelezzi A, Moia M, Falanga A, CATHEM Study Group, et al. Incidence of thrombotic complications in patients with haematological malignancies with Central venous catheters: a prospective multicentre study. Br J Haematol. 2005;129(6):811–817.
   PubMed Web of Science ®Google Scholar
• Bagratuni T, Kastritis E, Politou M, et al. Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide‐based regimens. Am J Hematol. 2013;88(9):765–770.
   PubMed Web of Science ®Google Scholar
• Chalayer E, Tardy‐Poncet B, Karlin L, et al. Thrombin generation in newly diagnosed multiple myeloma during the first three cycles of treatment: an observational cohort study. Res Pract Thromb Haemost. 2019;3(1):89–98.
   PubMed Web of Science ®Google Scholar
• Undas A, Zubkiewicz-Usnarska L, Helbig G, et al. Induction therapy alters plasma fibrin clot properties in multiple myeloma patients: association with thromboembolic complications. Blood Coagul Fibrinolysis. 2015;126(6):621–627.
   Google Scholar
• Leiba M, Malkiel S, Budnik I, et al. Thrombin generation as a predictor of thromboembolic events in multiple myeloma patients. Blood Cells Mol Dis. 2017;65:1–7.
   PubMed Web of Science ®Google Scholar
• Dargaud Y, Fouassier M, Bordet JC, et al. The challenge of myeloma-related thromboembolic disease: can thrombin generation assay help physicians to better predict the thromboembolic risk and personalize anti-thrombotic prophylaxis? Leuk Lymphoma. 2019;60(10):2572–2575.
   PubMed Web of Science ®Google Scholar
• Ay C, Simanek R, Vormittag R, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the vienna cancer and thrombosis study (CATS). Blood. 2008;112(7):2703–2708.
   PubMed Web of Science ®Google Scholar
• Zangari M, Barlogie B, Thertulien R, et al. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin Lymphoma. 2003;4(1):32–35.
   PubMedGoogle Scholar
• Pal R, Monaghan SA, Hassett AC, et al. Immunomodulatory derivatives induce PU. 1 down-regulation, myeloid maturation arrest, and neutropenia. Blood. 2010;115(3):605–614.
   PubMed Web of Science ®Google Scholar
• Dixon D. Venous thromboembolism prophylaxis in multiple myeloma patients. US Pharm. 2013;38(3):8–11.
   Google Scholar
• Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014;123(12):1826–1832.
   PubMed Web of Science ®Google Scholar
• San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(11):1055–1066.
   PubMed Web of Science ®Google Scholar
• Zangari M, Fink L, Zhan F, et al. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens. Clin Lymphoma Myeloma Leuk. 2011;11(2):228–236.
   PubMed Web of Science ®Google Scholar
• Piedra K, Peterson T, Tan C, et al. Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis. Br J Haematol. 2022;196(1):105–109.
   PubMed Web of Science ®Google Scholar
• Wang J, Kim Y. Risk of thromboembolism in patients with multiple myeloma treated with daratumumab: a systemic review and meta-analysis. Int J Hematol. 2020;112(5):650–657.
   PubMed Web of Science ®Google Scholar
• Mushtaq M, Nam TS, Kim UH. Critical role for CD38-mediated Ca2+ signaling in thrombin-induced procoagulant activity of mouse platelets and hemostasis. J Biol Chem. 2011;286(15):12952–12958.
   PubMed Web of Science ®Google Scholar
• Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. The Lancet. 2019;394(10214):2096–2107.
   PubMed Web of Science ®Google Scholar
• Moreau P, Dimopoulos MA, Yong K, et al. Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA phase III study design. Future Oncol. 2020;16(2):4347–4358.
   PubMed Web of Science ®Google Scholar
• Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21(2):207–221.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902–4907.
   PubMed Web of Science ®Google Scholar
• Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019;380(8):711–719.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Soff GA, Kakkar AK, CASSINI Investigators, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019;380(8):720–728.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Rajkumar SV, Dimopoulos MA, on behalf of the International Myeloma Working Group, et al. Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22(2):414–423.
   PubMed Web of Science ®Google Scholar
• Sanfilippo KM, Luo S, Wang TF, et al. Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. Am J Hematol. 2019;94(11):1176–1184.
   PubMed Web of Science ®Google Scholar
• Li A, Wu Q, Luo S, et al. Derivation and validation of a risk assessment model for immunomodulatory drug–associated thrombosis among patients with multiple myeloma. J Natl Compr Canc Netw. 2019;17(7):840–847.
   PubMed Web of Science ®Google Scholar
• Robak M, Treliński J, Chojnowski K. Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma. Med Oncol. 2012;29(5):3574–3580.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Palladino C. Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance. Ther Adv Drug Saf. 2012;3(5):255–266.
   PubMedGoogle Scholar
• Larocca A, Cavallo F, Bringhen S, et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood. 2012;119(4):933–939.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Cavo M, Bringhen S, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol. 2011;29(8):986–993.
   PubMed Web of Science ®Google Scholar
• Chakraborty R, Bin Riaz I, Malik SU, et al. Venous thromboembolism risk with contemporary lenalidomide‐based regimens despite thromboprophylaxis in multiple myeloma: a systematic review and Meta‐analysis. Cancer. 2020;126(8):1640–1650.
   PubMed Web of Science ®Google Scholar
• Al-Ani F, Bermejo JM, Mateos MV, et al. Thromboprophylaxis in multiple myeloma patients treated with lenalidomide–a systematic review. Thrombosis Res. 2016;141:84–90.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Gussoni G, Bianchini C, PROTECHT Investigators, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009;10(10):943–949.
   PubMed Web of Science ®Google Scholar
• Levine MN, Gu C, Liebman HA, et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost. 2012;10(5):807–814.
   PubMed Web of Science ®Google Scholar
• Man L, Morris A, Brown J, et al. Use of direct oral anticoagulants in patients on immunomodulatory agents. J Thromb Thrombolysis. 2017;44(3):298–302.
   PubMed Web of Science ®Google Scholar
• Storrar NP, Mathur A, Johnson PR, et al. Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide-and lenalidomide-containing regimens. Br J Haematol. 2019;185(1):142–144.
   PubMed Web of Science ®Google Scholar
• Cornell RF, Goldhaber SZ, Engelhardt BG, et al. Apixaban for primary prevention of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory therapy. Front Oncol. 2019;9:45.
   PubMed Web of Science ®Google Scholar
• Pegourie B, Karlin L, Benboubker L, IFM Group, et al. Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study. Am J Hematol. 2019;94(6):635–640.
   PubMed Web of Science ®Google Scholar
• Sayar Z, Czuprynska J, Patel JP, et al. What are the difficulties in conducting randomized controlled trials of thromboprophylaxis in myeloma patients and how can we address these? Lessons from apixaban versus LMWH or aspirin as thromboprophylaxis in newly diagnosed multiple myeloma (TiMM) feasibility clinical trial. J Thromb Thrombolysis. 2019;48(2):315–322.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Carrier M, Ay C, et al. American society of hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927–974.
   PubMed Web of Science ®Google Scholar
• Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38(5):496–520.
   PubMed Web of Science ®Google Scholar
• Farge D, Frere C, Connors JM, International Initiative on Thrombosis and Cancer (ITAC) advisory panel, et al. 2019 International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019;20(10):e566-81–e581.
   Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN guideline on cancer‐associated venous thromboembolic disease. Version 1. 2020. [cited 2022 Jan 05]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/vte.pdf.
   Google Scholar